醋酸戈舍瑞林缓释植入剂长期应用对前列腺癌患者去势后的临床疗效与安全性

发布时间：2018-05-25 01:00

本文选题：醋酸戈舍瑞林缓释植入剂 + 前列腺癌　；参考：《中国临床药理学杂志》2017年14期

【摘要】：目的观察醋酸戈舍瑞林缓释植入剂长期应用对前列腺癌患者去势后的临床疗效及安全性。方法 42例前列腺癌患者随机分为对照组及试验组,每组21例。双侧睾丸切除术后,对照组给予口服比卡鲁胺片50 mg qd;试验组在对照组基础上加用醋酸戈舍瑞林缓释植入剂3.60 mg,每28 d一次,腹前壁皮下注射。2组均持续治疗6个月。比较2组患者治疗前后血清前列腺特异性抗原、α-甲酰基辅酶A消旋酶水平、总有效率及安全性。结果治疗后,试验组和对照组的总有效率分别为90.48%(19/21例)和61.91%(13/21例),差异有统计学意义(P0.05)。治疗后,试验组和对照组患者血清前列腺特异性抗原(PSA)分别为(6.74±0.73),(13.27±1.17)μg·L-1;α-甲酰基辅酶A消旋酶(P504S)水平分别为(1.26±0.12),(1.85±0.21)μg·L-1,差异均有统计学意义(P0.05)。试验组的药物不良反应主要有潮热4例,乏力2例,腹泻1例,乳房肿痛2例,对照组的药物不良反应主要有潮热3例,乏力3例,乳房肿痛2例。试验组和对照组的药物不良反应发生率分别为42.86%(9/21例)和38.09%(8/21例),差异无统计学意义(P0.05)。结论醋酸戈舍瑞林缓释植入剂长期应用能够显著降低前列腺癌患者去势后患者的血清前列腺特异性抗原、α-甲酰基辅酶A消旋酶水平,提高临床疗效,安全性较高。
[Abstract]:Objective to observe the efficacy and safety of coserelin acetate sustained release implantation in patients with prostate cancer after castration. Methods 42 patients with prostate cancer were randomly divided into control group and experimental group with 21 cases in each group. After bilateral orchiectomy, the control group was given oral Carous Amine tablet 50mg QD, and the experimental group was treated continuously for 6 months by subcutaneous injection of Goserrelin Acetate 3.60 mg per 28 days on the basis of the control group. The serum prostatic specific antigen and 伪 -formyl coenzyme A racemase levels were compared before and after treatment in two groups. The total effective rate and safety were compared. Results after the treatment, the total effective rates of the test group and the control group were 90.48 / 19 / 21 and 61.91 / 13 / 21, respectively. The difference was statistically significant (P 0.05). After treatment, the serum prostatic specific antigen (PSAs) of patients in the experimental group and the control group were 6.74 卤0.73, 13.27 卤1.17 渭 g / L, and the levels of 伪 -formylcoA racemase P504S were 1.26 卤0.12, 1.85 卤0.21 渭 g / L, respectively, with statistical significance (P 0.05). There were 4 cases of hot flashes, 2 cases of asthenia, 1 case of diarrhea and 2 cases of breast swelling and pain in the experimental group. The adverse drug reactions in the control group were mainly hot flashes in 3 cases, asthenia in 3 cases, and breast swelling and pain in 2 cases. The incidence of adverse drug reactions in the trial group and the control group were 42.86 / 9 / 21 and 38.09% respectively. There was no significant difference between the two groups in the incidence of adverse drug reactions (P 0.05). Conclusion the long-term application of coserelin acetate implants can significantly reduce the serum prostate-specific antigen and 伪 -formyl coenzyme A racemase level in patients with prostate cancer after castration, and improve the clinical efficacy and safety.
【作者单位】：内江市第一人民医院泌尿外科;
【基金】：四川省卫生厅科研课题基金资助项目(120466)
【分类号】：R737.25

【参考文献】